Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus
This study demonstrated a statistically significant difference in vancomycin minimum inhibitory concentration (MIC) for Staphylococcus aureus between a common automated system (Vitek 2) and the E-test method in patients with S. aureus bloodstream infections. At an area under the serum concentration...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2016-09-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2079-6382/5/4/34 |
| _version_ | 1811257373328670720 |
|---|---|
| author | Seenae Eum Robert L. Bergsbaken Craig L. Harvey J. Bryan Warren John C. Rotschafer |
| author_facet | Seenae Eum Robert L. Bergsbaken Craig L. Harvey J. Bryan Warren John C. Rotschafer |
| author_sort | Seenae Eum |
| collection | DOAJ |
| description | This study demonstrated a statistically significant difference in vancomycin minimum inhibitory concentration (MIC) for Staphylococcus aureus between a common automated system (Vitek 2) and the E-test method in patients with S. aureus bloodstream infections. At an area under the serum concentration time curve (AUC) threshold of 400 mg∙h/L, we would have reached the current Infectious Diseases Society of America (IDSA)/American Society of Health System Pharmacists (ASHP)/Society of Infectious Diseases Pharmacists (SIDP) guideline suggested AUC/MIC target in almost 100% of patients while using the Vitek 2 MIC data; however, we could only generate 40% target attainment while using E-test MIC data (p < 0.0001). An AUC of 450 mg∙h/L or greater was required to achieve 100% target attainment using either Vitek 2 or E-test MIC results. |
| first_indexed | 2024-04-12T17:56:26Z |
| format | Article |
| id | doaj.art-3c15974c47a04dfa962795d0a3929ce7 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-04-12T17:56:26Z |
| publishDate | 2016-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-3c15974c47a04dfa962795d0a3929ce72022-12-22T03:22:20ZengMDPI AGAntibiotics2079-63822016-09-01543410.3390/antibiotics5040034antibiotics5040034Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureusSeenae Eum0Robert L. Bergsbaken1Craig L. Harvey2J. Bryan Warren3John C. Rotschafer4Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USADepartment of Lab Microbiology, Regions Hospital, Saint Paul, MN 55101, USADepartment of Pharmacy, Regions Hospital, Saint Paul, MN 55101, USADepartment of Medicine, Regions Hospital, Saint Paul, MN 55101, USADepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USAThis study demonstrated a statistically significant difference in vancomycin minimum inhibitory concentration (MIC) for Staphylococcus aureus between a common automated system (Vitek 2) and the E-test method in patients with S. aureus bloodstream infections. At an area under the serum concentration time curve (AUC) threshold of 400 mg∙h/L, we would have reached the current Infectious Diseases Society of America (IDSA)/American Society of Health System Pharmacists (ASHP)/Society of Infectious Diseases Pharmacists (SIDP) guideline suggested AUC/MIC target in almost 100% of patients while using the Vitek 2 MIC data; however, we could only generate 40% target attainment while using E-test MIC data (p < 0.0001). An AUC of 450 mg∙h/L or greater was required to achieve 100% target attainment using either Vitek 2 or E-test MIC results.http://www.mdpi.com/2079-6382/5/4/34vancomycinMICStaphylococcus aureussusceptibility testing |
| spellingShingle | Seenae Eum Robert L. Bergsbaken Craig L. Harvey J. Bryan Warren John C. Rotschafer Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus Antibiotics vancomycin MIC Staphylococcus aureus susceptibility testing |
| title | Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus |
| title_full | Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus |
| title_fullStr | Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus |
| title_full_unstemmed | Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus |
| title_short | Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus |
| title_sort | discrepancy in vancomycin auc mic ratio targeted attainment based upon the susceptibility testing in staphylococcus aureus |
| topic | vancomycin MIC Staphylococcus aureus susceptibility testing |
| url | http://www.mdpi.com/2079-6382/5/4/34 |
| work_keys_str_mv | AT seenaeeum discrepancyinvancomycinaucmicratiotargetedattainmentbaseduponthesusceptibilitytestinginstaphylococcusaureus AT robertlbergsbaken discrepancyinvancomycinaucmicratiotargetedattainmentbaseduponthesusceptibilitytestinginstaphylococcusaureus AT craiglharvey discrepancyinvancomycinaucmicratiotargetedattainmentbaseduponthesusceptibilitytestinginstaphylococcusaureus AT jbryanwarren discrepancyinvancomycinaucmicratiotargetedattainmentbaseduponthesusceptibilitytestinginstaphylococcusaureus AT johncrotschafer discrepancyinvancomycinaucmicratiotargetedattainmentbaseduponthesusceptibilitytestinginstaphylococcusaureus |